<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879905</url>
  </required_header>
  <id_info>
    <org_study_id>CHSP990A2101</org_study_id>
    <secondary_id>2008-006440-19</secondary_id>
    <nct_id>NCT00879905</nct_id>
  </id_info>
  <brief_title>A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally in Adult Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will study the safety, tolerability and metabolism of a drug called HSP990 when
      given by mouth once a week or twice weekly to subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of HSP990 in patients treated once weekly or twice weekly</measure>
    <time_frame>At the end of the dose escalation phase of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>True DLT rate</measure>
    <time_frame>At the end of the 1st 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy</measure>
    <time_frame>Every 2 months (or 8 weeks, which equals 2 treatment cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug metabolism in Humans, PK, PD</measure>
    <time_frame>every 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>once weekly dosing schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>twice weekly dosing schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSP990</intervention_name>
    <arm_group_label>once weekly dosing schedule</arm_group_label>
    <arm_group_label>twice weekly dosing schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed, advanced malignant solid tumors whose disease
             has progressed on standard therapy or for whom no standard therapy exists

          2. All patients must have at least one measurable lesion as defined by RECIST. Irradiated
             lesions are only evaluable for disease progression

          3. All patients must have documented progressive disease before entering the study

          4. Age ≥ 18 years

          5. World Health Organization (WHO) Performance Status ≤ 2

          6. Life expectancy of ≥ 12 weeks

          7. Patients must have the certain laboratory values

          8. Patients able and willing to swallow capsules

          9. Ability to understand the patient information and informed consent form and comply
             with the protocol

         10. Signed and dated written informed consent is available

         11. Only for patients enrolled at MTD: willing to provide a fresh pre-dose and post-dose
             tumor biopsy.

        Exclusion Criteria:

          1. Patients with present or history of CNS metastasis.

          2. Prior treatment with any Hsp90 or HDAC inhibitor compound.

          3. Patients who have not recovered from side effects of previous systemic anticancer
             therapy to &lt; CTCAE Grade 2 prior to the first dose

          4. Patients identified to be &quot;poor or intermediate CYP2C9 metabolizers&quot;

          5. Patients who received systemic anti-cancer treatment prior to the first dose of HSP990
             within the following time frames:

               -  Patients who have received cyclical chemotherapy within a period of time that is
                  shorter than the cycle length used for that treatment (e.g., 6 weeks for
                  nitrosourea, mitomycin-C) prior to starting study drug or who have not recovered
                  from the side effects of such therapy

               -  Patients who have received biologic therapy (e.g., antibodies) within a period of
                  time that is ≤ 4 weeks prior to starting study drug or who have not recovered
                  from the side effects of such therapy

               -  Patients who have been treated with a continuous or intermittent small molecule
                  therapeutic within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks (whichever is
                  shorter) prior to starting study drug or who have not recovered from the side
                  effects of such therapy

               -  Patients who have received any other investigational agents within a period of
                  time that is ≤ 5 t1/2 or less than the cycle length used for that treatment or ≤
                  4 weeks (whichever is shorter) prior to starting study drug or who have not
                  recovered from the side effects of such therapy

               -  Patients who have received wide field radiotherapy (including therapeutic
                  radioisotopes such as strontium 89) ≤ 4 weeks or limited field radiation for
                  palliation ≤ 2 weeks prior to starting study drug or who have not recovered from
                  side effects of such therapy.

               -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug
                  or who have not recovered from side effects of such therapy

          6. Treatment with therapeutic doses of sodium warfarin (Coumadin).

          7. Patients using medications that are CYP2C9 inhibitors and/or medications known to have
             QT prolongation effect and cannot be switched or discontinued to an alternative drug
             prior to commencing HSP990 dosing.

          8. Unresolved diarrhea ≥ CTCAE grade 2

          9. Patients who do not have either an archival tumor sample available or readily
             obtainable in the course of the study or are unwilling to have a fresh tumor sample
             collected at baseline.

         10. Pregnant or lactating women.

         11. Fertile women of childbearing potential (WCBP) not using adequate contraception
             (abstinence, oral contraceptives, intrauterine device or barrier method of
             contraception in conjunction with spermicidal jelly or surgically sterile). Male
             patients whose partners are WCBP, not using adequate contraception.

         12. Acute or chronic liver disease.

         13. Acute or chronic renal disease.

         14. Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of HSP990

         15. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled
             diabetes, active or uncontrolled infection) that could cause unacceptable safety risks
             or compromise compliance with the protocol.

         16. Known diagnosis of HIV infection (HIV testing is not mandatory).

         17. Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention

         18. Cardiac exclusion criteria:

               -  History (or family history) of long QT syndrome.

               -  Mean QTcF ≥ 480 msec on screening ECG

               -  History of clinically manifest ischemic heart disease including myocardial
                  infarction, or unstable angina ≤ 3 months prior to study start.

               -  Left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO

               -  Clinically significant ECG abnormalities including one or more of the following:
                  left bundle branch block (LBBB), right bundle branch block (RBBB) with left
                  anterior hemiblock (LAHB), or 3rd degree AV block.

               -  History or presence of atrial fibrillation, atrial flutter or ventricular
                  arrhythmias including ventricular tachycardia or Torsades de Pointes.

               -  Clinically significant resting bradycardia (&lt; 50 beats per minute).

               -  Patients who are currently receiving treatment with any medication which has a
                  relative risk or prolonging the QTcF interval or inducing Torsades de Pointes (as
                  listed in Post-text supplement 2) and cannot be switched or discontinued to an
                  alternative drug prior to commencing HSP990 dosing.

               -  Obligate use of a cardiac pacemaker.

               -  Other clinically significant heart disease (e.g., congestive heart failure,
                  uncontrolled hypertension, history of labile hypertension, or history of poor
                  compliance with an antihypertensive regimen)

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 3</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2009</study_first_submitted>
  <study_first_submitted_qc>April 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2009</study_first_posted>
  <last_update_submitted>October 18, 2012</last_update_submitted>
  <last_update_submitted_qc>October 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Adults</keyword>
  <keyword>HSP990</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Hsp90 inhibitor</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

